Cargando…

Disrupting the Molecular Pathway in Myotonic Dystrophy

Myotonic dystrophy is the most common muscular dystrophy in adults. It consists of two forms: type 1 (DM1) and type 2 (DM2). DM1 is associated with a trinucleotide repeat expansion mutation, which is transcribed but not translated into protein. The mutant RNA remains in the nucleus, which leads to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Xiaomeng, Kumari, Anjani, Brown, Jake, Brook, John David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708683/
https://www.ncbi.nlm.nih.gov/pubmed/34948025
http://dx.doi.org/10.3390/ijms222413225
_version_ 1784622746840334336
author Xing, Xiaomeng
Kumari, Anjani
Brown, Jake
Brook, John David
author_facet Xing, Xiaomeng
Kumari, Anjani
Brown, Jake
Brook, John David
author_sort Xing, Xiaomeng
collection PubMed
description Myotonic dystrophy is the most common muscular dystrophy in adults. It consists of two forms: type 1 (DM1) and type 2 (DM2). DM1 is associated with a trinucleotide repeat expansion mutation, which is transcribed but not translated into protein. The mutant RNA remains in the nucleus, which leads to a series of downstream abnormalities. DM1 is widely considered to be an RNA-based disorder. Thus, we consider three areas of the RNA pathway that may offer targeting opportunities to disrupt the production, stability, and degradation of the mutant RNA.
format Online
Article
Text
id pubmed-8708683
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87086832021-12-25 Disrupting the Molecular Pathway in Myotonic Dystrophy Xing, Xiaomeng Kumari, Anjani Brown, Jake Brook, John David Int J Mol Sci Review Myotonic dystrophy is the most common muscular dystrophy in adults. It consists of two forms: type 1 (DM1) and type 2 (DM2). DM1 is associated with a trinucleotide repeat expansion mutation, which is transcribed but not translated into protein. The mutant RNA remains in the nucleus, which leads to a series of downstream abnormalities. DM1 is widely considered to be an RNA-based disorder. Thus, we consider three areas of the RNA pathway that may offer targeting opportunities to disrupt the production, stability, and degradation of the mutant RNA. MDPI 2021-12-08 /pmc/articles/PMC8708683/ /pubmed/34948025 http://dx.doi.org/10.3390/ijms222413225 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Xing, Xiaomeng
Kumari, Anjani
Brown, Jake
Brook, John David
Disrupting the Molecular Pathway in Myotonic Dystrophy
title Disrupting the Molecular Pathway in Myotonic Dystrophy
title_full Disrupting the Molecular Pathway in Myotonic Dystrophy
title_fullStr Disrupting the Molecular Pathway in Myotonic Dystrophy
title_full_unstemmed Disrupting the Molecular Pathway in Myotonic Dystrophy
title_short Disrupting the Molecular Pathway in Myotonic Dystrophy
title_sort disrupting the molecular pathway in myotonic dystrophy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708683/
https://www.ncbi.nlm.nih.gov/pubmed/34948025
http://dx.doi.org/10.3390/ijms222413225
work_keys_str_mv AT xingxiaomeng disruptingthemolecularpathwayinmyotonicdystrophy
AT kumarianjani disruptingthemolecularpathwayinmyotonicdystrophy
AT brownjake disruptingthemolecularpathwayinmyotonicdystrophy
AT brookjohndavid disruptingthemolecularpathwayinmyotonicdystrophy